BERWYN, Pa., April 02, 2025 (GLOBE NEWSWIRE) --

宾夕法尼亚州伯温，2025年4月2日（环球新闻社）--

AscellaHealth

阿斯塞拉健康

, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today unveiled its latest

，一家为特色制药行业提供可定制解决方案的全球合作伙伴，今天发布了其最新的

Specialty & Rare Pipeline Digest

专业与稀有管道摘要

™,

™,

the industry’s most comprehensive digital resource for information on new, pending and upcoming specialty and rare disease drug launches and approvals, biosimilars and cell and gene therapies (CGTs). As the intricate specialty pharmaceutical landscape evolves with emerging therapies, this complimentary quarterly publication equips stakeholders with vital, timely updates into specialty product pipelines..

该行业最全面的数字资源，提供有关新的、待定的和即将推出的专业及罕见病药物上市和批准、生物仿制药以及细胞和基因疗法 (CGT) 的信息。随着专业制药领域新兴疗法的不断发展，这份免费的季刊为利益相关者提供了关于专业产品管线的重要且及时的更新。

'The steady pace of FDA approvals for novel therapies and shifts in treatment approaches, especially in the specialty and orphan drug areas, highlight the demand for these timely, actionable insights to advance treatment options for complex and rare conditions,” says Andy Szczotka, PharmD, chief pharmacy officer, AscellaHealth.

“FDA对新型疗法的审批步伐稳定，治疗方式也在不断变化，特别是在专科和孤儿药领域，这些及时、可操作的见解对于推进复杂和罕见病的治疗选择需求凸显，”AscellaHealth首席药剂官安迪·什乔特卡（Andy Szczotka）博士表示。

“Developed by our talented and dedicated team of clinical researchers and analytics experts, this robust publication empowers manufacturers, payers and providers with the knowledge to strategically navigate this dynamic landscape, supporting our commitment to enhancing patient access to treatment and product affordability.'.

“这份强大的出版物由我们才华横溢且敬业的临床研究人员和分析专家团队开发，为制造商、支付方和供应商提供了战略性地驾驭这一动态格局的知识，支持我们提高患者获得治疗的机会和产品可负担性的承诺。”

A Look Back: 2024

回顾：2024

In 2024, the FDA approved

2024年，FDA批准了

50 novel drugs

50种新药

, slightly fewer than the 55 approved in 2023, but still above the 10-year average of 47 approvals annually. Over half of these new drugs target rare or orphan diseases. Furthermore,

，略少于2023年批准的55种，但仍然高于每年47种的十年平均值。其中超过一半的新药针对罕见病或孤儿病。此外，

66%

66%

of the approvals were fast-tracked through at least one of the FDA's expedited programs designed to address serious health conditions, with 16% receiving accelerated approval, reflecting a continued drive for innovation in patient care and the potential to enhance public health.

其中的审批是通过FDA至少一个旨在解决严重健康问题的快速通道项目加速完成的，16%获得了加速批准，反映出在患者护理方面的持续创新动力以及提升公共健康的潜力。

Projected Trends: 2025-2026

预测趋势：2025-2026

Projections

投影

for 2025–2026 indicate that trends will remain similar to those of 2024–2025, despite the introduction of several high-cost treatments for rare diseases. Specialty drugs are expected to continue growing as a significant portion of overall drug spending, with these medications accounting for more than half of total drug expenditures in 2025-2026 and beyond..

预计 2025-2026 年的趋势将与 2024-2025 年类似，尽管会引入几种用于罕见病的高成本治疗药物。专科药物预计将继续增长，占整体药品支出的很大一部分，到 2025-2026 年及以后，这些药物将占总药品支出的一半以上。

Growth in Specialty and Orphan Drug Approvals:

专业药物和孤儿药批准的增长：

The FDA’s focus on specialty medications and orphan drugs continues to expand, with

FDA对专科药物和孤儿药的关注持续扩大，

71%

71%

of recent submissions being for specialty medications and 34% for orphan drugs. This trend reflects a growing commitment to addressing complex and rare conditions through innovative treatments.

近期提交的申请中，针对特种药物的申请占比较大，其中34%为孤儿药。这一趋势反映出通过创新治疗手段解决复杂和罕见疾病问题的决心日益增强。

Read more findings in the latest Specialty & Rare Pipeline Digest™

在最新的《专科与罕见病管道摘要™》中阅读更多发现

here

这里

.

。

About AscellaHealth LLC

关于AscellaHealth有限责任公司

AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma.

AscellaHealth 是一家全球合作伙伴，为生命科学和医疗保健公司提供经过验证的端到端解决方案，以提高患有复杂慢性病的患者的生活质量。一支专业团队将关键的医疗产品从制造商送到患者手中，同时确保支付方与制药公司之间的资金流动高效顺畅。

Visit .

访问。

www.AscellaHealth.com

www.AscellaHealth.com

.

。

A photo accompanying this announcement is available at

随此公告附带的照片可以在

https://www.globenewswire.com/NewsRoom/AttachmentNg/9f14bad2-92c2-429a-b11e-d33acd247fe7

https://www.globenewswire.com/NewsRoom/AttachmentNg/9f14bad2-92c2-429a-b11e-d33acd247fe7

This press release was published by a CLEAR® Verified individual.

本新闻稿由一名CLEAR®认证的个人发布。